Immunotherapy for ALL takes the world by storm

被引：0
|
作者：
David T. Teachey
Stephen P. Hunger
机构：
[1] The Center for Childhood Cancer Research,David T. Teachey and Stephen P. Hunger are at the Department of Pediatrics
[2] Children's Hospital of Philadelphia,undefined
[3] and the Perelman School of Medicine,undefined
[4] University of Pennsylvania,undefined
[5] 3400 Civic Center Boulevard,undefined
[6] Philadelphia,undefined
[7] Pennsylvania 19104,undefined
[8] USA.,undefined
来源：
Nature Reviews Clinical Oncology | 2018年 / 15卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In 2017, three groundbreaking immunotherapies for relapsed and/or refractory B-cell acute lymphoblastic leukaemia (ALL) were approved based on impressive outcomes observed in clinical trials. Additional breakthroughs included seminal research into ALL genomics and the importance of adherence to chemotherapy, which will have direct implications for clinical care.
引用
收藏
页码：69 / 70
页数：1
相关论文
共 50 条
12345